

# The impact of diuretic use and *ABCG2* genotype on the predictive performance of a published allopurinol dosing tool

**Running head:** Impact of diuretic use and *ABCG2* genotype on allopurinol dosing

Daniel F B Wright<sup>1</sup>, Nicola Dalbeth<sup>2</sup>, Amanda J Phipps-Green<sup>3</sup>, Tony R Merriman<sup>3</sup>, Murray L Barclay<sup>4,5</sup>, Jill Drake<sup>4</sup>, Paul Tan<sup>2</sup>, Anne Horne<sup>2</sup>, Lisa K Stamp<sup>4</sup>

<sup>1</sup>School of Pharmacy, University of Otago, Dunedin, New Zealand

<sup>2</sup>Department of Medicine, University of Auckland, Auckland, New Zealand

<sup>3</sup>Department of Biochemistry, University of Otago, Dunedin, New Zealand

<sup>4</sup>Department of Medicine, University of Otago, Christchurch, New Zealand

<sup>5</sup>Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand

## Author for correspondence:

Daniel F.B. Wright

School of Pharmacy, University of Otago

PO Box 56, Dunedin, New Zealand, 9054

email: [dan.wright@otago.ac.nz](mailto:dan.wright@otago.ac.nz)

tel: +64 3 479-7290, fax: +64 3 479 7034

**Key Words:** Allopurinol, gout, diuretics, urate, *ABCG2*, genotype

**Word count:** 1699

**Figures:** 1

**Tables:** 2 (2 Supplementary Tables)

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.13516

## ABSTRACT

This research aims to evaluate the predictive performance of a published allopurinol dosing tool. Allopurinol dose predictions were compared to the actual dose required to achieve serum urate (SU)  $<0.36 \text{ mmol L}^{-1}$  using mean prediction error. The influence of patient factors on dose predictions was explored using multilinear regression. Allopurinol doses were over-predicted by the dosing tool, however, this was minimal in patients without diuretic therapy (MPE  $63 \text{ mg day}^{-1}$ , 95%CI 40-87) compared to those receiving diuretics (MPE  $295 \text{ mg day}^{-1}$ , 95%CI 260-330,  $p < 0.0001$ ). *ABCG2* genotype (rs2231142, G>T) had an important impact on the dose predictions (MPE 201, 107,  $15 \text{ mg day}^{-1}$  for GG, GT and TT, respectively,  $p < 0.0001$ ). Diuretic use and *ABCG2* genotype explained 53% of the variability in prediction error ( $R^2 = 0.53$ ,  $p = 0.0004$ ). The dosing tool produced acceptable maintenance dose predictions for patients not taking diuretics. Inclusion of *ABCG2* genotype and a revised adjustment for diuretics would further improve the performance of the dosing tool.

### What is already known about this subject?

- The maintenance dose of allopurinol required to achieve target SU ( $<0.36 \text{ mmol L}^{-1}$ ) is highly variable between individuals.
- To date, there has been little research to identify patient factors that impact allopurinol dose requirements and could aid dosing decisions in the clinic.
- A recently published dosing tool for allopurinol suggested that renal function, weight, and diuretic use would determine the maintenance dose requirements, but this tool has not been evaluated against data from an independent cohort of people with gout.

### What this study adds?

- The allopurinol dosing tool produced reasonably accurate and precise maintenance dose predictions for patients not taking diuretics.
- Concomitant diuretic therapy resulted in a profound over-prediction of allopurinol dose and, for this reason, we recommend that the non-diuretic dose predictions from the published dosing tool be used for all patients, regardless of diuretic use.
- Inclusion of *ABCG2* genotype (rs2231142, G>T) and a revised adjustment for diuretics would further improve the performance of the dosing tool.

## INTRODUCTION

Treat-to-target serum urate (SU) is a key strategy in the long-term management of gout.<sup>1,2</sup> While allopurinol is a first line urate-lowering therapy<sup>2</sup>, many people fail to achieve target SU due to restricted dosing, particularly in those with kidney disease.<sup>3-5</sup> There is increasing evidence to support the use of allopurinol at doses above those based on kidney function to achieve target SU.<sup>6,7</sup> The initiation of allopurinol therapy requires the use of low doses, with a gradual increase based on serum urate response and tolerability. However, the dose of allopurinol that will ultimately be required to achieve target SU ( $<0.36\text{mmol L}^{-1}$ ) is highly variable between individuals.<sup>3-8</sup>

The patient factors that determine allopurinol dose requirements are not well understood. Recent studies have found that renal function, diuretic use, probenecid use, and body weight have an important impact on oxypurinol clearance (the active metabolite of allopurinol).<sup>9,10</sup> Some cardiovascular drugs have been associated with lower serum urate concentrations and may enhance allopurinol response (e.g. losartan<sup>11</sup>) while others are reported to increase hyperuricemia risk and may be anticipated to diminish allopurinol response (e.g. beta-blockers<sup>11</sup>).

Recent work on the genetic determinants of gout have found that variants of apical and basolateral urate transporters in the kidney and gut are associated with hyperuricaemia and gout risk.<sup>12,13</sup> In the case of ABCG2, which encodes the efflux transporter Breast Cancer Resistant Protein (BRCP), a reduced function allele rs2231142 (Q141K, G>T) has been associated with poor allopurinol response,<sup>14</sup> hyperuricemia,<sup>15</sup> and the presence of tophi.<sup>16</sup> To date, there has been little research designed to quantify the impact of these factors on allopurinol maintenance dose requirements and which could therefore aid dosing decisions in the clinic.

We have previously developed a pharmacokinetic-pharmacodynamic (PKPD) model for allopurinol in people with gout.<sup>8</sup> We identified body weight, diuretic use, and, to a lesser extent, kidney function estimated using creatinine clearance (CLCr, as defined by Cockcroft and Gault<sup>17</sup>) as key factors influencing allopurinol urate-lowering response. Model predictions of urate lowering under different values of CLCr, weight, and with and without concomitant diuretics, were used to produce a dosing tool to guide dosing decisions. The tool, in the form of a dosing table, is presented in the Supplementary Material (herein termed the 'Otago dosing tool'). To date, the tool has not been evaluated against data from an independent cohort of people with gout. The aims of this study were; 1) to evaluate the predictive performance of the Otago dosing tool against an evaluation dataset, and, 2) to determine the influence of patient factors (including genetic variants in urate transporters<sup>12,13</sup>) on predicted doses.

## **METHODS**

### **Evaluation Dataset**

Data from a published randomised controlled trial<sup>6,7</sup> (RCT) comparing CLCr-based dosing (based on Hande et al<sup>18</sup>) to a dose escalation protocol were analysed. In brief, 183 people with gout on allopurinol with  $SU \geq 0.36 \text{ mmol L}^{-1}$  were randomised to either continue their current dose of allopurinol for 12 months and then undergo dose escalation or to begin allopurinol dose escalation immediately. During dose-escalation, allopurinol was increased monthly until SU was  $<0.36 \text{ mmol L}^{-1}$ . Blood samples for the measurement of SU, creatinine, and plasma oxypurinol were obtained at least three-monthly. Co-author LKS was the principle investigator of the RCT. The study was approved by the New Zealand Health and Disabilities Ethics Committee and prospectively registered with the Australian New Zealand Clinical Trials Registry (ANZCTR12611000845932). All participants gave written, informed consent.

## Genotyping

Single nucleotide polymorphisms (SNPs) in urate transporter variants associated with hyperuricemia or gout<sup>12,13</sup> were analysed using TaqMan® assays (Applied Biosystems, Foster City); rs11942223 (*SLC2A9*), rs2231142 (Q141K, *ABCG2*), rs10011796 (*ABCG2*), rs1183201 (*NPT1/SLC17A1*), rs17300741 (*OAT4*), and rs3825018 (*URAT1*). Details of the genotypes are presented in the Supplementary Material.

## Definition of observed dose

The observed dose was defined as the dose required by the participant to achieve  $SU < 0.36 \text{ mmol L}^{-1}$  on two consecutive visits. Participants were excluded if they failed to achieve the SU target on two consecutive visits while taking the same dose of allopurinol, were receiving dialysis, or had plasma oxypurinol  $< 20 \mu\text{mol L}^{-1}$ , below which non-adherence is considered likely.<sup>3,4</sup> Patient characteristics were recorded for each participant on the same clinic visit as the observed dose. For missing patient characteristics, the last observation was carried forward. In the case of missing genotype data, the patient was excluded from the analysis.

## Definition of model-predicted dose

Model-predicted doses for each participant were determined by referring to the published Otago dosing tool (see supplementary material). Renal function, weight and diuretic-use were recorded for each patient on the second of two clinic visits where the target urate was achieved (as above for the observed dose). In this way, the predicted dose and observed dose were aligned to the same clinic visit. The dose predictions are intended to signal the likely allopurinol dose required to achieve  $SU < 0.36 \text{ mmol L}^{-1}$  given differences in kidney function, weight and diuretic use.

## Data analysis

The observed and predicted maintenance doses were compared using mean prediction error [MPE]) as a measure of bias<sup>19</sup>, given by;

$$pe_i = \text{predicted dose}_i - \text{observed dose}_i$$

$$MPE = \frac{1}{N} \sum_{i=1}^N pe_i$$

where  $pe_i$  is the prediction error for the  $i^{th}$  individual, and  $N$  is the number of participants. If the 95% confidence interval of MPE included zero then no bias was concluded. The proportion of dose predictions within 100mg from the observed dose was determined as a measure of precision.

Further analyses explored the influence of kidney function, weight, ethnicity, sex, concomitant drugs, and urate transporters genotype on the predictive performance of the model-based dosing tool. For categorical variables, the marginal influence on MPE was assessed using a t-test and/or ANOVA. The marginal influence of continuous variables on prediction error was assessed using linear regression analysis in Prism (v7.03, GraphPad, La Jolla, CA). A significant relationship was concluded if the 95% confidence interval of the slope of the regression line did not include zero. p-values were considered significant if  $p < 0.05$ . A multilinear regression analysis to assess the joint influence of patient factors on the variability in prediction error was conducted in R (v3.2.2, The R Foundation).

## Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY,<sup>20</sup> and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18.<sup>21</sup>

## RESULTS

Allopurinol doses and SU concentrations were available for 183 people with gout. Thirty-four participants who did not achieve target SU, three receiving dialysis, and two with plasma oxypurinol  $<20\mu\text{mol L}^{-1}$ , were excluded from the analysis. Data for one participant with an implausible dose response relationship was also excluded (assumed non-adherence). The final dataset included 143 participants. Demographics and clinical features are outlined in Table 1. Genotype information is summarised in the Supplemental Material.

A summary of the MPE, and imprecision results are presented in Table 2 and Figure 1. MPE was greater than zero indicating an over-predicted dose (MPE  $150\text{mg day}^{-1}$ , 95%CI 125-175) (Figure 1a). The over-prediction was substantially lower in participants without concomitant diuretic therapy (MPE  $63\text{mg day}^{-1}$ , 95%CI 40-87). A profound over-prediction was observed in participants taking diuretics (MPE  $295\text{mg day}^{-1}$ , 95%CI 260-330) (Figure 1b). The predicted doses were within 100mg of the observed allopurinol dose in 68% of participants not receiving diuretics compared to only 13% receiving diuretics. No differences were observed between loop and thiazide diuretics (Table 2). No other patient characteristics were found to influence the dose predictions (see Supplementary material for plots of prediction error against CL<sub>cr</sub> and weight).

The MPE was significantly influenced by *ABCG2* (rs2231142) genotype (MPE 201, 107, 15  $\text{mg day}^{-1}$ , GG, GT and TT respectively,  $p<0.0001$ ) (Table 1, Figure 1c). This genotype effect appears to have been largely retained in those with and without concomitant diuretics (Table 1, Figure 1d). There was no identifiable influence of the other genotypes tested on dose predictions.

The multilinear regression results are presented in the Supplementary material. *ABCG2* genotype and diuretic use explained 53% of the variability in PE (adjusted  $R^2=0.53$ ,

$p=0.0008$ ). Diuretic use was estimated to over-predict the dose by about 170mg/day ( $p=0.0084$ ) while the GG genotype over-predicted the dose by 94mg/day ( $p=0.036$ ). No other patient factors were found to significantly influence dose predictions in the multilinear regression analysis (see Supplementary material). Inclusion of interaction terms in the regression to account for correlation between patient factors did not improve the model fit and was not explored further.

## DISCUSSION

We have observed that the Otago dosing tool over-estimated dose requirements by about 150mg daily. Concomitant diuretic therapy appears to be a major source of the over-prediction. For those patients not taking diuretics, the dosing tool showed reasonable accuracy and precision. The residual over-prediction of about 63mg daily in those not taking diuretics is less than the smallest available tablet size (100mg) and likely to be of minimal clinical importance. When the diuretic effect in the published dosing table is ignored by using the non-diuretic dose predictions for all patients, regardless of diuretic use, the over-prediction was found to be similar at about 70mg daily (see supplemental material, supplemental Figure 3). We propose that using the non-diuretic dose predictions for all patients is a pragmatic solution until the diuretic effect on allopurinol dose requirements can be clarified.

The reason for the over-prediction in allopurinol doses by the Otago tool for individuals taking diuretics is unclear. The diuretic effect estimated in the original pharmacokinetic-pharmacodynamic model used to develop the tool was a 25% reduction in oxypurinol clearance and 14% increase in baseline SU concentrations on average<sup>8</sup>. This is broadly similar to the diuretic effect reported elsewhere for allopurinol therapy.<sup>9,22</sup> The original PKPD model was developed using a dataset of 134 patients. Of these, 24 had pre-treatment

SU concentrations available and, of those, only 10 were taking a diuretic. This means that the impact of diuretic therapy on urate-lowering was estimated in the model-building analysis from only 10 individuals. This introduces the risk of type 1 statistical error and may have resulted in an inflated diuretic effect. Re-estimation of the diuretic effect using the additional data from the RCT will be needed to clarify the magnitude of the diuretic effect.

*ABCG2* genotype had an important impact on dose predictions. Our results align with published work where the T-allele has also been associated with poor allopurinol response<sup>14</sup>, hyperuricemia<sup>15</sup>, and the presence of tophi.<sup>16</sup> The inference is that patients carrying the T allele will have a reduced efflux of urate and will therefore require higher allopurinol doses to achieve the target urate response. Examination of the observed doses required to achieve the urate target in the RCT (evaluation) data used for this analysis found a significant difference between the three genotypes (344, 427, 489 mg daily for the GG, GT and TT genotype respectively,  $p < 0.0001$ ). In the current study, model-based dose predictions were unbiased for the TT genotype, but were over-predicted for the GT and GG genotype. This suggests that adjustment for the genotype effect, resulting in lower predicted doses for those with the GG and GT genotype, should significantly improve the predictive performance of the model-based dosing tool.

The small residual over-prediction in those subjects not taking diuretics (about  $63\text{mg day}^{-1}$ ) could speculatively be attributed to differences in adherence between the cohorts used for model-building and model-evaluation. The model-building data included some small, intensively sampled, studies using selected cohorts of patients where good adherence might be expected. To limit the impact of non-adherence in the evaluation data, the first dose to achieve the target urate after the start of the study was used, rather than the dose observed at the end of the study. It is also acknowledged that we cannot rule type 1 statistical error in the

dose predictions in those with different ABCG2 genotypes, given the low numbers with the TT genotype.

In summary, the allopurinol dosing tool produced reasonably accurate and precise maintenance dose predictions for patients not taking diuretics. Concomitant diuretic therapy resulted in an over-prediction of allopurinol dose and, for this reason, we recommend that the non-diuretic dose predictions from the published dosing tool be used for all patients, regardless of diuretic use. Inclusion of ABCG2 genotype and a revised adjustment for diuretics would further improve the performance of the Otago dosing tool.

## **ACKNOWLEDGEMENTS**

We wish to thank Stephen Duffull and Chihiro Hasegawa, School of Pharmacy, University of Otago for advice on the data analysis. We thank Dr Mei Zhang, Canterbury Health Laboratories for her work with the oxypurinol assay. The RCT and genetics data were originally collected as part of research supported by the Health Research Council of New Zealand.

## **Conflicts of interest/ disclosure**

All authors have completed the Unified Competing Interest form at [http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author). DFBW, JD, AP-G, PT and AH declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. ND discloses consulting fees, speaker fees or grants from Takeda, Menarini, Teijin, Pfizer, Ardea Biosciences, AstraZeneca, Amgen, Horizon, and Cymabay. LKS declares speaker fees from Amgen and grants from Ardea Biosciences. TRM declares research funding from Ardea Biosciences and consulting fees from Ironwood Pharmaceuticals

## REFERENCES

1. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. *Arthritis Care Res* 2012; 64:1431–46.
2. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis* 2017;76:29–42.
3. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. *Arthritis Rheum* 2011;63:412–21.
4. Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. *Clin Pharmacol Ther* 2011;90:392–8.
5. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. *J Rheumatol* 2006;33:1646–50.
6. Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. *Ann Rheum Dis* 2017;76:1522–28.
7. Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan Pan, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. *Ann Rheum Dis* 2017;Aug 22, DOI: 10.1136/annrheumdis-2017-211873.
8. Wright DFB, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. *Br J Clin Pharmacol* 2016;81:277–89.
9. Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, et al. The pharmacokinetics of oxypurinol in people with gout. *Br J Clin Pharmacol* 2012;74:477–89.
10. Wright DFB, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. *Eur J Clin Pharmacol* 2013;69:1411–21.
11. Reyes AJ. Cardiovascular drugs and serum uric acid. *Cardiovasc Drugs Ther* 2003;17:397–414.
12. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet* 2013;45:145–54.
13. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. *Joint Bone Spine* 2011;78:35–40.
14. Wen CC, Yee SW, Liang X, Hoffman TJ, Kvale MN, Banda Y, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. *Clin Pharmacol Ther* 2015;97:518–25.

15. Kannangara DRW, Phipps-Green AJ, Dalbeth N, Stamp LK, Williams KM, Graham GG, *et al.* Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. *Arthritis Care Res* 2016;75:1363–66.
16. He W, Phipps-Green AJ, Stamp LK, Merriman TR, Dalbeth N. Population-specific association between ABCG2 variants and tophaceous disease in people with gout. *Arthritis Res Ther* 2017;19:43.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976 16:31-41.
18. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. *Am J Med* 1984;76:47–56.
19. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. *J Pharmacokinet Biopharm* 1981;9:503-12.
20. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, *et al.* The IUPHAR/BPS Guide to Pharmacology in 2018: updates and expansion to encompass the new guide to Immunopharmacology. *Nucl Acid Res* 2018; 46: D1091-106.
21. Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA, *et al.* The Concise Guide to Pharmacology 2017/18: Transporters. *Brit J Pharmacol* 2017;174: S360–S446.
22. Stamp LK, Barclay M, O'Donnell JL, Zhang M, Drake J, Frampton C, *et al.* Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: implications for clinical practice. *Rheumatology* 2012;51:1670-6.

Accepted

**Table 1** Demographic and clinical details of the external dataset

	Total (n=143)
Males (n [%])	126 [88%]
Age (years)	62 [23-86]
Weight (kg)	104 [64-177]
European (n [%])	70 [49%]
Pacific Island (n [%])	39 [27%]
Māori (n [%])	27 [19%]
South Asian <sup>^</sup> (n [%])	4 [3%]
East Asian (n [%])	3 [2%]
CLcr (mL/min) <sup>@</sup>	61 [11-150]
Diuretics (n [%]) <sup>#</sup>	53 [37 %]
Beta-blockers (n [%])	60 [42 %]
Angiotensin converting enzyme inhibitors (n [%])	78 [55%]
Angiotensin II receptor blockers (n [%])	17 [12%]
Calcium channel blockers (n [%])	33 [23%]
HMG-CoA reductase inhibitor (n [%])	75 [52%]
Uricosuric (n [%])	5 [3.5 %]
Allopurinol dose at target SU (mg/day)	350 [100-700]
Oxypurinol at target SU ( $\mu\text{mol L}^{-1}$ ) <sup>%</sup>	105 [30-512]
Pre-treatment urate ( $\text{mmol L}^{-1}$ ) <sup>*</sup>	0.61 [0.36-0.89]
Urate at target ( $\text{mmol L}^{-1}$ )	5.4 [3.5-6.0]


All data expressed as median [range] unless otherwise stated. <sup>^</sup> = the subjects of Southern Asian ancestry were all Indian, M/F = male/female, CLcr = creatinine clearance. <sup>@</sup>creatinine clearance determined using the Cockcroft-Gault equation.<sup>17</sup> <sup>#</sup>Diuretics included n=40 loop (39 x frusemide, 1 x bumetanide), n=13 thiazides (10 x hydrochlorothiazide, 3 x bendrofluzide) and n=1 spironolactone. <sup>%</sup>Oxypurinol plasma concentrations were measured at the comparison clinic visit for 110 individuals. <sup>\*</sup>Pre-treatment urate concentrations were available for 53 individuals.

**Table 2** A summary of observed and predicted doses, mean prediction error, and precision

	<b>Observed dose* (mg d<sup>-1</sup>)</b>	<b>Predicted dose* (mg d<sup>-1</sup>)</b>	<b>MPE (mg d<sup>-1</sup>)</b>	<b>95% CI (MPE)</b>	<b>RMSE (mg d<sup>-1</sup>)</b>	<b>+/- 100mg of observed (%)</b>
All data (n=143)	385	535	150	125-175	222	47%
<b>Diuretic therapy<sup>^+</sup></b>						
No diuretic (n=89)	391	454	63	40-87	129	68%
Diuretics (n=54)	373	668	295	260-330	317	13%
Loop (n=40)	381	672	291	247-335		-
Thiazides (n=13)	369	661	292	237-347		-
<b>Transporter genotype# *</b>						
ABCG2 GG (n=80)	344	545	201	166-236	255	40%
No diuretic (n=44)	351	448	97	68-126	135	68%
Diuretics (n=36)	335	664	329	289-369	349	6%
ABCG2 GT (n=49)	427	534	107	68-146	171	59%
No diuretic (n=35)	419	474	55	22-89	111	71%
Diuretics (n=14)	446	682	236	159-312	268	21%
ABCG2 TT (n=13)	481	496	15	-99-129	182	38%
No diuretic (n=9)	489	422	-67	-187-53	162	44%
Diuretics (n=4)	463	663	200	28-372	221	25%

\*observed and predicted doses expressed as the mean, <sup>^</sup> diuretic therapy included loop (frusemide), and thiazide diuretics. One individual was taking spironolactone. <sup>+</sup>Differences in PE between those taking and not taking diuretics assessed by a t-test ( $p < 0.0001$ ). \*Differences in PE between ABCG2 genotypes (GG, GT, and TT) assessed using a one-way ANOVA ( $p < 0.0001$ ). Post-hoc t-tests assessed differences in prediction error between ABCG2 genotypes; GG vrs GT ( $p = 0.007$ ), GG vrs TT ( $p = 0.0002$ ), and, GT vrs TT ( $p = 0.05$ ). Differences in PE for those with and without concomitant diuretic therapy stratified by ABCG2 genotype was assessed by t-test as follows; GG genotype no diuretic vrs diuretic ( $p < 0.0001$ ), GT genotype no diuretic vrs diuretic ( $p < 0.001$ ) and TT genotype no diuretic vrs diuretic ( $p = 0.0107$ ). CI – confidence interval, MPE = mean prediction error. #one patient with missing ABCG2 genotype data was omitted from the analysis.

Accept



**Figure 1** Data plots for observed doses, predicted doses, and prediction error. Figure 1A: Relationship between the observed and predicted allopurinol maintenance doses. Figure 1B: Relationship between the observed and predicted allopurinol maintenance doses in those with and without concomitant diuretics. Figure 1C: Box plots of raw prediction error for each genotype of *ABCG2* (rs2231142). Differences in prediction error between *ABCG2* genotypes were assessed by ANOVA ( $p < 0.0001$ ) and by t-test, i.e. GG vs GT ( $p = 0.007$ ), GG vs TT ( $p = 0.0002$ ), and, GT vs TT ( $p = 0.05$ ). Figure 1D: Box plots of raw prediction error for each genotype of *ABCG2* (rs2231142) in those with and without concomitant diuretics. Differences in prediction error between *ABCG2* genotypes for those not taking diuretics were assessed by ANOVA ( $p = 0.0002$ ) and by t-test, i.e. GG vs GT ( $p = 0.0001$ ), GG vs TT ( $p = 0.065$ ), and, GT vs TT ( $p = 0.0052$ ). Differences in prediction error between *ABCG2*

genotypes for those taking diuretics were assessed by ANOVA ( $p=0.0183$ ) and by t-test, i.e. wGG vrs GT ( $p=0.0432$ ), GG vrs TT ( $p=0.0188$ ), and, GT vrs TT ( $p=0.63$ ).

Differences in PE for those with and without concomitant diuretic therapy stratified by ABCG2 genotype was assessed by t-test as follows; GG genotype no diuretic vrs diuretic ( $p<0.0001$ ), GT genotype no diuretic vrs diuretic ( $p<0.001$ ) and TT genotype no diuretic vrs diuretic ( $p=0.0107$ ).

Accepted Article